Review



p-aurkb (t232) antibody  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Cell Signaling Technology Inc p-aurkb (t232) antibody
    P Aurkb (T232) Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p-aurkb (t232) antibody/product/Cell Signaling Technology Inc
    Average 90 stars, based on 1 article reviews
    p-aurkb (t232) antibody - by Bioz Stars, 2026-04
    90/100 stars

    Images



    Similar Products

    89
    Thermo Fisher gene exp aurkb mm01718146 g1
    Gene Exp Aurkb Mm01718146 G1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 89/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gene exp aurkb mm01718146 g1/product/Thermo Fisher
    Average 89 stars, based on 1 article reviews
    gene exp aurkb mm01718146 g1 - by Bioz Stars, 2026-04
    89/100 stars
      Buy from Supplier

    96
    Proteintech human aurkb protein
    A Immunoprecipitation assay indicates ZBP1 phosphorylation levels in 293T cells transfected with Myc-tagged ZBP1 and HA-tagged <t>AURKB</t> or its phosphonull TA mutants. Immunoprecipitated ZBP1 was probed with anti-phosphor-ser/thr antibody. B A schematic of the human ZBP1 sequence highlighting the phosphorylation sites observed by MS is shown. Fold changes in the abundance of phosphorylated peptides of ZBP1 in 293T cells transfected with AURKB-WT relative to 293T cells transfected with vectors are shown. Dots indicate data from three independent experiments. Additionally, fold changes in the abundance of phosphorylated peptides of ZBP1 in 293T cells transfected with AURKB-TA relative to 293T cells transfected with AURKB-WT are shown. C , D After the KD of ZBP1, OVCAR8 cells were transfected with plasmids expressing Myc-tagged ZBP1 or its phosphonull mutants and then were subjected to 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h. Immunoblot analysis of ZBP1, GSDME, PARP1, pMLKL, and tMLKL. GAPDH was used as the internal control. E The S309 phosphorylation site of ZBP1 in 293T cells after treated with 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h was analyzed by LC-MS/MS. F – I After the KD of ZBP1, OVCAR8 cells were transfected with plasmids expressing Myc-tagged ZBP1 or its phosphonull S309A mutants and then were subjected to 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h. F Phase-contrast imaging assay of OVCAR8 cells. The red arrowheads indicate the large bubbles emerging from the plasma membrane. Scale bar = 100 μm. Representative images ( G ) and quantification ( H ) of the PI+ cells (red) and YP1+ cells (green). Scale bar = 100 μm. I Comparison of LDH release-based cell death. J The validation of ZBP1-S309 antibody using dot-blot assay. The vertical axis represents the concentration of the antibody. K In vitro phosphorylation assay of ZBP1 by purified protein AURKB <t>or</t> <t>CDK1.</t> L Immunoblot analysis in OVCAR8 cells after treated by 250 nM Talazoparib and 2.5 μM Ceralasertib and/or 1 μM Barasertib for 24 h. M After treating with 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h, OVCAR8 cells were shaken off to enrich mitotic cells and then treated with 1 μM Barasertib for 6 h. Immunoblot analysis of pAURKB, AURKB, pZBP1, and ZBP1 in OVCAR8 cells. GAPDH was used as the internal control. Representative images ( N ) and quantification ( O ) of the PLA to detect the physical association between AURKB and pZBP1-S309. Scale bar = 20 μm. P CO-IP assay to assess the interactions among ZBP1, RIPK1, CASP8, and CASP6 after transfected with Myc-tagged ZBP1 or its phosphonull S309A mutants and treated with 250 nM Talazoparib and 2.5 μM Ceralasertib in 293T cells. CASP8: caspase 8, CASP6: caspase 6. Q Schematic overview of the mechanism of DDR inhibitors-induced PANoptosis during aberrant mitotic progression. Created in BioRender. Liao, Z. (2025) https://BioRender.com/bstbek5 . The data in ( H , I , O ) are representative of three independent experiments and presented as the mean ± SEM. Data were repeated thrice independently in ( A , C , D , F , K – M , P ) with similar results. Statistical significance was determined using two-tailed Student’s t test in ( O ) and one-way ANOVA with Tukey’s multiple comparisons test in ( H , I ). Source data are provided as a file.
    Human Aurkb Protein, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human aurkb protein/product/Proteintech
    Average 96 stars, based on 1 article reviews
    human aurkb protein - by Bioz Stars, 2026-04
    96/100 stars
      Buy from Supplier

    90
    Absolute Biotech Inc aurkb antibody ls-b1451
    A Immunoprecipitation assay indicates ZBP1 phosphorylation levels in 293T cells transfected with Myc-tagged ZBP1 and HA-tagged <t>AURKB</t> or its phosphonull TA mutants. Immunoprecipitated ZBP1 was probed with anti-phosphor-ser/thr antibody. B A schematic of the human ZBP1 sequence highlighting the phosphorylation sites observed by MS is shown. Fold changes in the abundance of phosphorylated peptides of ZBP1 in 293T cells transfected with AURKB-WT relative to 293T cells transfected with vectors are shown. Dots indicate data from three independent experiments. Additionally, fold changes in the abundance of phosphorylated peptides of ZBP1 in 293T cells transfected with AURKB-TA relative to 293T cells transfected with AURKB-WT are shown. C , D After the KD of ZBP1, OVCAR8 cells were transfected with plasmids expressing Myc-tagged ZBP1 or its phosphonull mutants and then were subjected to 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h. Immunoblot analysis of ZBP1, GSDME, PARP1, pMLKL, and tMLKL. GAPDH was used as the internal control. E The S309 phosphorylation site of ZBP1 in 293T cells after treated with 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h was analyzed by LC-MS/MS. F – I After the KD of ZBP1, OVCAR8 cells were transfected with plasmids expressing Myc-tagged ZBP1 or its phosphonull S309A mutants and then were subjected to 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h. F Phase-contrast imaging assay of OVCAR8 cells. The red arrowheads indicate the large bubbles emerging from the plasma membrane. Scale bar = 100 μm. Representative images ( G ) and quantification ( H ) of the PI+ cells (red) and YP1+ cells (green). Scale bar = 100 μm. I Comparison of LDH release-based cell death. J The validation of ZBP1-S309 antibody using dot-blot assay. The vertical axis represents the concentration of the antibody. K In vitro phosphorylation assay of ZBP1 by purified protein AURKB <t>or</t> <t>CDK1.</t> L Immunoblot analysis in OVCAR8 cells after treated by 250 nM Talazoparib and 2.5 μM Ceralasertib and/or 1 μM Barasertib for 24 h. M After treating with 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h, OVCAR8 cells were shaken off to enrich mitotic cells and then treated with 1 μM Barasertib for 6 h. Immunoblot analysis of pAURKB, AURKB, pZBP1, and ZBP1 in OVCAR8 cells. GAPDH was used as the internal control. Representative images ( N ) and quantification ( O ) of the PLA to detect the physical association between AURKB and pZBP1-S309. Scale bar = 20 μm. P CO-IP assay to assess the interactions among ZBP1, RIPK1, CASP8, and CASP6 after transfected with Myc-tagged ZBP1 or its phosphonull S309A mutants and treated with 250 nM Talazoparib and 2.5 μM Ceralasertib in 293T cells. CASP8: caspase 8, CASP6: caspase 6. Q Schematic overview of the mechanism of DDR inhibitors-induced PANoptosis during aberrant mitotic progression. Created in BioRender. Liao, Z. (2025) https://BioRender.com/bstbek5 . The data in ( H , I , O ) are representative of three independent experiments and presented as the mean ± SEM. Data were repeated thrice independently in ( A , C , D , F , K – M , P ) with similar results. Statistical significance was determined using two-tailed Student’s t test in ( O ) and one-way ANOVA with Tukey’s multiple comparisons test in ( H , I ). Source data are provided as a file.
    Aurkb Antibody Ls B1451, supplied by Absolute Biotech Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/aurkb antibody ls-b1451/product/Absolute Biotech Inc
    Average 90 stars, based on 1 article reviews
    aurkb antibody ls-b1451 - by Bioz Stars, 2026-04
    90/100 stars
      Buy from Supplier

    90
    Cell Signaling Technology Inc p-aurkb (t232) antibody
    A Immunoprecipitation assay indicates ZBP1 phosphorylation levels in 293T cells transfected with Myc-tagged ZBP1 and HA-tagged <t>AURKB</t> or its phosphonull TA mutants. Immunoprecipitated ZBP1 was probed with anti-phosphor-ser/thr antibody. B A schematic of the human ZBP1 sequence highlighting the phosphorylation sites observed by MS is shown. Fold changes in the abundance of phosphorylated peptides of ZBP1 in 293T cells transfected with AURKB-WT relative to 293T cells transfected with vectors are shown. Dots indicate data from three independent experiments. Additionally, fold changes in the abundance of phosphorylated peptides of ZBP1 in 293T cells transfected with AURKB-TA relative to 293T cells transfected with AURKB-WT are shown. C , D After the KD of ZBP1, OVCAR8 cells were transfected with plasmids expressing Myc-tagged ZBP1 or its phosphonull mutants and then were subjected to 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h. Immunoblot analysis of ZBP1, GSDME, PARP1, pMLKL, and tMLKL. GAPDH was used as the internal control. E The S309 phosphorylation site of ZBP1 in 293T cells after treated with 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h was analyzed by LC-MS/MS. F – I After the KD of ZBP1, OVCAR8 cells were transfected with plasmids expressing Myc-tagged ZBP1 or its phosphonull S309A mutants and then were subjected to 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h. F Phase-contrast imaging assay of OVCAR8 cells. The red arrowheads indicate the large bubbles emerging from the plasma membrane. Scale bar = 100 μm. Representative images ( G ) and quantification ( H ) of the PI+ cells (red) and YP1+ cells (green). Scale bar = 100 μm. I Comparison of LDH release-based cell death. J The validation of ZBP1-S309 antibody using dot-blot assay. The vertical axis represents the concentration of the antibody. K In vitro phosphorylation assay of ZBP1 by purified protein AURKB <t>or</t> <t>CDK1.</t> L Immunoblot analysis in OVCAR8 cells after treated by 250 nM Talazoparib and 2.5 μM Ceralasertib and/or 1 μM Barasertib for 24 h. M After treating with 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h, OVCAR8 cells were shaken off to enrich mitotic cells and then treated with 1 μM Barasertib for 6 h. Immunoblot analysis of pAURKB, AURKB, pZBP1, and ZBP1 in OVCAR8 cells. GAPDH was used as the internal control. Representative images ( N ) and quantification ( O ) of the PLA to detect the physical association between AURKB and pZBP1-S309. Scale bar = 20 μm. P CO-IP assay to assess the interactions among ZBP1, RIPK1, CASP8, and CASP6 after transfected with Myc-tagged ZBP1 or its phosphonull S309A mutants and treated with 250 nM Talazoparib and 2.5 μM Ceralasertib in 293T cells. CASP8: caspase 8, CASP6: caspase 6. Q Schematic overview of the mechanism of DDR inhibitors-induced PANoptosis during aberrant mitotic progression. Created in BioRender. Liao, Z. (2025) https://BioRender.com/bstbek5 . The data in ( H , I , O ) are representative of three independent experiments and presented as the mean ± SEM. Data were repeated thrice independently in ( A , C , D , F , K – M , P ) with similar results. Statistical significance was determined using two-tailed Student’s t test in ( O ) and one-way ANOVA with Tukey’s multiple comparisons test in ( H , I ). Source data are provided as a file.
    P Aurkb (T232) Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p-aurkb (t232) antibody/product/Cell Signaling Technology Inc
    Average 90 stars, based on 1 article reviews
    p-aurkb (t232) antibody - by Bioz Stars, 2026-04
    90/100 stars
      Buy from Supplier

    90
    Santa Cruz Biotechnology anti-aurkb
    A Immunoprecipitation assay indicates ZBP1 phosphorylation levels in 293T cells transfected with Myc-tagged ZBP1 and HA-tagged <t>AURKB</t> or its phosphonull TA mutants. Immunoprecipitated ZBP1 was probed with anti-phosphor-ser/thr antibody. B A schematic of the human ZBP1 sequence highlighting the phosphorylation sites observed by MS is shown. Fold changes in the abundance of phosphorylated peptides of ZBP1 in 293T cells transfected with AURKB-WT relative to 293T cells transfected with vectors are shown. Dots indicate data from three independent experiments. Additionally, fold changes in the abundance of phosphorylated peptides of ZBP1 in 293T cells transfected with AURKB-TA relative to 293T cells transfected with AURKB-WT are shown. C , D After the KD of ZBP1, OVCAR8 cells were transfected with plasmids expressing Myc-tagged ZBP1 or its phosphonull mutants and then were subjected to 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h. Immunoblot analysis of ZBP1, GSDME, PARP1, pMLKL, and tMLKL. GAPDH was used as the internal control. E The S309 phosphorylation site of ZBP1 in 293T cells after treated with 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h was analyzed by LC-MS/MS. F – I After the KD of ZBP1, OVCAR8 cells were transfected with plasmids expressing Myc-tagged ZBP1 or its phosphonull S309A mutants and then were subjected to 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h. F Phase-contrast imaging assay of OVCAR8 cells. The red arrowheads indicate the large bubbles emerging from the plasma membrane. Scale bar = 100 μm. Representative images ( G ) and quantification ( H ) of the PI+ cells (red) and YP1+ cells (green). Scale bar = 100 μm. I Comparison of LDH release-based cell death. J The validation of ZBP1-S309 antibody using dot-blot assay. The vertical axis represents the concentration of the antibody. K In vitro phosphorylation assay of ZBP1 by purified protein AURKB <t>or</t> <t>CDK1.</t> L Immunoblot analysis in OVCAR8 cells after treated by 250 nM Talazoparib and 2.5 μM Ceralasertib and/or 1 μM Barasertib for 24 h. M After treating with 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h, OVCAR8 cells were shaken off to enrich mitotic cells and then treated with 1 μM Barasertib for 6 h. Immunoblot analysis of pAURKB, AURKB, pZBP1, and ZBP1 in OVCAR8 cells. GAPDH was used as the internal control. Representative images ( N ) and quantification ( O ) of the PLA to detect the physical association between AURKB and pZBP1-S309. Scale bar = 20 μm. P CO-IP assay to assess the interactions among ZBP1, RIPK1, CASP8, and CASP6 after transfected with Myc-tagged ZBP1 or its phosphonull S309A mutants and treated with 250 nM Talazoparib and 2.5 μM Ceralasertib in 293T cells. CASP8: caspase 8, CASP6: caspase 6. Q Schematic overview of the mechanism of DDR inhibitors-induced PANoptosis during aberrant mitotic progression. Created in BioRender. Liao, Z. (2025) https://BioRender.com/bstbek5 . The data in ( H , I , O ) are representative of three independent experiments and presented as the mean ± SEM. Data were repeated thrice independently in ( A , C , D , F , K – M , P ) with similar results. Statistical significance was determined using two-tailed Student’s t test in ( O ) and one-way ANOVA with Tukey’s multiple comparisons test in ( H , I ). Source data are provided as a file.
    Anti Aurkb, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti-aurkb/product/Santa Cruz Biotechnology
    Average 90 stars, based on 1 article reviews
    anti-aurkb - by Bioz Stars, 2026-04
    90/100 stars
      Buy from Supplier

    90
    Cell Signaling Technology Inc antibody phospho-aurka t288 /aurkb t232 /aurkc t198
    A Immunoprecipitation assay indicates ZBP1 phosphorylation levels in 293T cells transfected with Myc-tagged ZBP1 and HA-tagged <t>AURKB</t> or its phosphonull TA mutants. Immunoprecipitated ZBP1 was probed with anti-phosphor-ser/thr antibody. B A schematic of the human ZBP1 sequence highlighting the phosphorylation sites observed by MS is shown. Fold changes in the abundance of phosphorylated peptides of ZBP1 in 293T cells transfected with AURKB-WT relative to 293T cells transfected with vectors are shown. Dots indicate data from three independent experiments. Additionally, fold changes in the abundance of phosphorylated peptides of ZBP1 in 293T cells transfected with AURKB-TA relative to 293T cells transfected with AURKB-WT are shown. C , D After the KD of ZBP1, OVCAR8 cells were transfected with plasmids expressing Myc-tagged ZBP1 or its phosphonull mutants and then were subjected to 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h. Immunoblot analysis of ZBP1, GSDME, PARP1, pMLKL, and tMLKL. GAPDH was used as the internal control. E The S309 phosphorylation site of ZBP1 in 293T cells after treated with 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h was analyzed by LC-MS/MS. F – I After the KD of ZBP1, OVCAR8 cells were transfected with plasmids expressing Myc-tagged ZBP1 or its phosphonull S309A mutants and then were subjected to 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h. F Phase-contrast imaging assay of OVCAR8 cells. The red arrowheads indicate the large bubbles emerging from the plasma membrane. Scale bar = 100 μm. Representative images ( G ) and quantification ( H ) of the PI+ cells (red) and YP1+ cells (green). Scale bar = 100 μm. I Comparison of LDH release-based cell death. J The validation of ZBP1-S309 antibody using dot-blot assay. The vertical axis represents the concentration of the antibody. K In vitro phosphorylation assay of ZBP1 by purified protein AURKB <t>or</t> <t>CDK1.</t> L Immunoblot analysis in OVCAR8 cells after treated by 250 nM Talazoparib and 2.5 μM Ceralasertib and/or 1 μM Barasertib for 24 h. M After treating with 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h, OVCAR8 cells were shaken off to enrich mitotic cells and then treated with 1 μM Barasertib for 6 h. Immunoblot analysis of pAURKB, AURKB, pZBP1, and ZBP1 in OVCAR8 cells. GAPDH was used as the internal control. Representative images ( N ) and quantification ( O ) of the PLA to detect the physical association between AURKB and pZBP1-S309. Scale bar = 20 μm. P CO-IP assay to assess the interactions among ZBP1, RIPK1, CASP8, and CASP6 after transfected with Myc-tagged ZBP1 or its phosphonull S309A mutants and treated with 250 nM Talazoparib and 2.5 μM Ceralasertib in 293T cells. CASP8: caspase 8, CASP6: caspase 6. Q Schematic overview of the mechanism of DDR inhibitors-induced PANoptosis during aberrant mitotic progression. Created in BioRender. Liao, Z. (2025) https://BioRender.com/bstbek5 . The data in ( H , I , O ) are representative of three independent experiments and presented as the mean ± SEM. Data were repeated thrice independently in ( A , C , D , F , K – M , P ) with similar results. Statistical significance was determined using two-tailed Student’s t test in ( O ) and one-way ANOVA with Tukey’s multiple comparisons test in ( H , I ). Source data are provided as a file.
    Antibody Phospho Aurka T288 /Aurkb T232 /Aurkc T198, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antibody phospho-aurka t288 /aurkb t232 /aurkc t198/product/Cell Signaling Technology Inc
    Average 90 stars, based on 1 article reviews
    antibody phospho-aurka t288 /aurkb t232 /aurkc t198 - by Bioz Stars, 2026-04
    90/100 stars
      Buy from Supplier

    90
    Biomatik human aurkb gene with 6x histidine affinity tag at n-terminal cloned in pet28a+ from
    A Immunoprecipitation assay indicates ZBP1 phosphorylation levels in 293T cells transfected with Myc-tagged ZBP1 and HA-tagged <t>AURKB</t> or its phosphonull TA mutants. Immunoprecipitated ZBP1 was probed with anti-phosphor-ser/thr antibody. B A schematic of the human ZBP1 sequence highlighting the phosphorylation sites observed by MS is shown. Fold changes in the abundance of phosphorylated peptides of ZBP1 in 293T cells transfected with AURKB-WT relative to 293T cells transfected with vectors are shown. Dots indicate data from three independent experiments. Additionally, fold changes in the abundance of phosphorylated peptides of ZBP1 in 293T cells transfected with AURKB-TA relative to 293T cells transfected with AURKB-WT are shown. C , D After the KD of ZBP1, OVCAR8 cells were transfected with plasmids expressing Myc-tagged ZBP1 or its phosphonull mutants and then were subjected to 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h. Immunoblot analysis of ZBP1, GSDME, PARP1, pMLKL, and tMLKL. GAPDH was used as the internal control. E The S309 phosphorylation site of ZBP1 in 293T cells after treated with 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h was analyzed by LC-MS/MS. F – I After the KD of ZBP1, OVCAR8 cells were transfected with plasmids expressing Myc-tagged ZBP1 or its phosphonull S309A mutants and then were subjected to 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h. F Phase-contrast imaging assay of OVCAR8 cells. The red arrowheads indicate the large bubbles emerging from the plasma membrane. Scale bar = 100 μm. Representative images ( G ) and quantification ( H ) of the PI+ cells (red) and YP1+ cells (green). Scale bar = 100 μm. I Comparison of LDH release-based cell death. J The validation of ZBP1-S309 antibody using dot-blot assay. The vertical axis represents the concentration of the antibody. K In vitro phosphorylation assay of ZBP1 by purified protein AURKB <t>or</t> <t>CDK1.</t> L Immunoblot analysis in OVCAR8 cells after treated by 250 nM Talazoparib and 2.5 μM Ceralasertib and/or 1 μM Barasertib for 24 h. M After treating with 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h, OVCAR8 cells were shaken off to enrich mitotic cells and then treated with 1 μM Barasertib for 6 h. Immunoblot analysis of pAURKB, AURKB, pZBP1, and ZBP1 in OVCAR8 cells. GAPDH was used as the internal control. Representative images ( N ) and quantification ( O ) of the PLA to detect the physical association between AURKB and pZBP1-S309. Scale bar = 20 μm. P CO-IP assay to assess the interactions among ZBP1, RIPK1, CASP8, and CASP6 after transfected with Myc-tagged ZBP1 or its phosphonull S309A mutants and treated with 250 nM Talazoparib and 2.5 μM Ceralasertib in 293T cells. CASP8: caspase 8, CASP6: caspase 6. Q Schematic overview of the mechanism of DDR inhibitors-induced PANoptosis during aberrant mitotic progression. Created in BioRender. Liao, Z. (2025) https://BioRender.com/bstbek5 . The data in ( H , I , O ) are representative of three independent experiments and presented as the mean ± SEM. Data were repeated thrice independently in ( A , C , D , F , K – M , P ) with similar results. Statistical significance was determined using two-tailed Student’s t test in ( O ) and one-way ANOVA with Tukey’s multiple comparisons test in ( H , I ). Source data are provided as a file.
    Human Aurkb Gene With 6x Histidine Affinity Tag At N Terminal Cloned In Pet28a+ From, supplied by Biomatik, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human aurkb gene with 6x histidine affinity tag at n-terminal cloned in pet28a+ from/product/Biomatik
    Average 90 stars, based on 1 article reviews
    human aurkb gene with 6x histidine affinity tag at n-terminal cloned in pet28a+ from - by Bioz Stars, 2026-04
    90/100 stars
      Buy from Supplier

    90
    Shanghai GenePharma sh- rnas specifically targeting aurkb sh- aurkb- 1, sh- aurkb- 2, and sh- aurkb- 3
    A Immunoprecipitation assay indicates ZBP1 phosphorylation levels in 293T cells transfected with Myc-tagged ZBP1 and HA-tagged <t>AURKB</t> or its phosphonull TA mutants. Immunoprecipitated ZBP1 was probed with anti-phosphor-ser/thr antibody. B A schematic of the human ZBP1 sequence highlighting the phosphorylation sites observed by MS is shown. Fold changes in the abundance of phosphorylated peptides of ZBP1 in 293T cells transfected with AURKB-WT relative to 293T cells transfected with vectors are shown. Dots indicate data from three independent experiments. Additionally, fold changes in the abundance of phosphorylated peptides of ZBP1 in 293T cells transfected with AURKB-TA relative to 293T cells transfected with AURKB-WT are shown. C , D After the KD of ZBP1, OVCAR8 cells were transfected with plasmids expressing Myc-tagged ZBP1 or its phosphonull mutants and then were subjected to 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h. Immunoblot analysis of ZBP1, GSDME, PARP1, pMLKL, and tMLKL. GAPDH was used as the internal control. E The S309 phosphorylation site of ZBP1 in 293T cells after treated with 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h was analyzed by LC-MS/MS. F – I After the KD of ZBP1, OVCAR8 cells were transfected with plasmids expressing Myc-tagged ZBP1 or its phosphonull S309A mutants and then were subjected to 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h. F Phase-contrast imaging assay of OVCAR8 cells. The red arrowheads indicate the large bubbles emerging from the plasma membrane. Scale bar = 100 μm. Representative images ( G ) and quantification ( H ) of the PI+ cells (red) and YP1+ cells (green). Scale bar = 100 μm. I Comparison of LDH release-based cell death. J The validation of ZBP1-S309 antibody using dot-blot assay. The vertical axis represents the concentration of the antibody. K In vitro phosphorylation assay of ZBP1 by purified protein AURKB <t>or</t> <t>CDK1.</t> L Immunoblot analysis in OVCAR8 cells after treated by 250 nM Talazoparib and 2.5 μM Ceralasertib and/or 1 μM Barasertib for 24 h. M After treating with 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h, OVCAR8 cells were shaken off to enrich mitotic cells and then treated with 1 μM Barasertib for 6 h. Immunoblot analysis of pAURKB, AURKB, pZBP1, and ZBP1 in OVCAR8 cells. GAPDH was used as the internal control. Representative images ( N ) and quantification ( O ) of the PLA to detect the physical association between AURKB and pZBP1-S309. Scale bar = 20 μm. P CO-IP assay to assess the interactions among ZBP1, RIPK1, CASP8, and CASP6 after transfected with Myc-tagged ZBP1 or its phosphonull S309A mutants and treated with 250 nM Talazoparib and 2.5 μM Ceralasertib in 293T cells. CASP8: caspase 8, CASP6: caspase 6. Q Schematic overview of the mechanism of DDR inhibitors-induced PANoptosis during aberrant mitotic progression. Created in BioRender. Liao, Z. (2025) https://BioRender.com/bstbek5 . The data in ( H , I , O ) are representative of three independent experiments and presented as the mean ± SEM. Data were repeated thrice independently in ( A , C , D , F , K – M , P ) with similar results. Statistical significance was determined using two-tailed Student’s t test in ( O ) and one-way ANOVA with Tukey’s multiple comparisons test in ( H , I ). Source data are provided as a file.
    Sh Rnas Specifically Targeting Aurkb Sh Aurkb 1, Sh Aurkb 2, And Sh Aurkb 3, supplied by Shanghai GenePharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sh- rnas specifically targeting aurkb sh- aurkb- 1, sh- aurkb- 2, and sh- aurkb- 3/product/Shanghai GenePharma
    Average 90 stars, based on 1 article reviews
    sh- rnas specifically targeting aurkb sh- aurkb- 1, sh- aurkb- 2, and sh- aurkb- 3 - by Bioz Stars, 2026-04
    90/100 stars
      Buy from Supplier

    90
    Shanghai GenePharma pcdna3.1- aurkb plasmid
    A Immunoprecipitation assay indicates ZBP1 phosphorylation levels in 293T cells transfected with Myc-tagged ZBP1 and HA-tagged <t>AURKB</t> or its phosphonull TA mutants. Immunoprecipitated ZBP1 was probed with anti-phosphor-ser/thr antibody. B A schematic of the human ZBP1 sequence highlighting the phosphorylation sites observed by MS is shown. Fold changes in the abundance of phosphorylated peptides of ZBP1 in 293T cells transfected with AURKB-WT relative to 293T cells transfected with vectors are shown. Dots indicate data from three independent experiments. Additionally, fold changes in the abundance of phosphorylated peptides of ZBP1 in 293T cells transfected with AURKB-TA relative to 293T cells transfected with AURKB-WT are shown. C , D After the KD of ZBP1, OVCAR8 cells were transfected with plasmids expressing Myc-tagged ZBP1 or its phosphonull mutants and then were subjected to 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h. Immunoblot analysis of ZBP1, GSDME, PARP1, pMLKL, and tMLKL. GAPDH was used as the internal control. E The S309 phosphorylation site of ZBP1 in 293T cells after treated with 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h was analyzed by LC-MS/MS. F – I After the KD of ZBP1, OVCAR8 cells were transfected with plasmids expressing Myc-tagged ZBP1 or its phosphonull S309A mutants and then were subjected to 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h. F Phase-contrast imaging assay of OVCAR8 cells. The red arrowheads indicate the large bubbles emerging from the plasma membrane. Scale bar = 100 μm. Representative images ( G ) and quantification ( H ) of the PI+ cells (red) and YP1+ cells (green). Scale bar = 100 μm. I Comparison of LDH release-based cell death. J The validation of ZBP1-S309 antibody using dot-blot assay. The vertical axis represents the concentration of the antibody. K In vitro phosphorylation assay of ZBP1 by purified protein AURKB <t>or</t> <t>CDK1.</t> L Immunoblot analysis in OVCAR8 cells after treated by 250 nM Talazoparib and 2.5 μM Ceralasertib and/or 1 μM Barasertib for 24 h. M After treating with 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h, OVCAR8 cells were shaken off to enrich mitotic cells and then treated with 1 μM Barasertib for 6 h. Immunoblot analysis of pAURKB, AURKB, pZBP1, and ZBP1 in OVCAR8 cells. GAPDH was used as the internal control. Representative images ( N ) and quantification ( O ) of the PLA to detect the physical association between AURKB and pZBP1-S309. Scale bar = 20 μm. P CO-IP assay to assess the interactions among ZBP1, RIPK1, CASP8, and CASP6 after transfected with Myc-tagged ZBP1 or its phosphonull S309A mutants and treated with 250 nM Talazoparib and 2.5 μM Ceralasertib in 293T cells. CASP8: caspase 8, CASP6: caspase 6. Q Schematic overview of the mechanism of DDR inhibitors-induced PANoptosis during aberrant mitotic progression. Created in BioRender. Liao, Z. (2025) https://BioRender.com/bstbek5 . The data in ( H , I , O ) are representative of three independent experiments and presented as the mean ± SEM. Data were repeated thrice independently in ( A , C , D , F , K – M , P ) with similar results. Statistical significance was determined using two-tailed Student’s t test in ( O ) and one-way ANOVA with Tukey’s multiple comparisons test in ( H , I ). Source data are provided as a file.
    Pcdna3.1 Aurkb Plasmid, supplied by Shanghai GenePharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pcdna3.1- aurkb plasmid/product/Shanghai GenePharma
    Average 90 stars, based on 1 article reviews
    pcdna3.1- aurkb plasmid - by Bioz Stars, 2026-04
    90/100 stars
      Buy from Supplier

    Image Search Results


    A Immunoprecipitation assay indicates ZBP1 phosphorylation levels in 293T cells transfected with Myc-tagged ZBP1 and HA-tagged AURKB or its phosphonull TA mutants. Immunoprecipitated ZBP1 was probed with anti-phosphor-ser/thr antibody. B A schematic of the human ZBP1 sequence highlighting the phosphorylation sites observed by MS is shown. Fold changes in the abundance of phosphorylated peptides of ZBP1 in 293T cells transfected with AURKB-WT relative to 293T cells transfected with vectors are shown. Dots indicate data from three independent experiments. Additionally, fold changes in the abundance of phosphorylated peptides of ZBP1 in 293T cells transfected with AURKB-TA relative to 293T cells transfected with AURKB-WT are shown. C , D After the KD of ZBP1, OVCAR8 cells were transfected with plasmids expressing Myc-tagged ZBP1 or its phosphonull mutants and then were subjected to 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h. Immunoblot analysis of ZBP1, GSDME, PARP1, pMLKL, and tMLKL. GAPDH was used as the internal control. E The S309 phosphorylation site of ZBP1 in 293T cells after treated with 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h was analyzed by LC-MS/MS. F – I After the KD of ZBP1, OVCAR8 cells were transfected with plasmids expressing Myc-tagged ZBP1 or its phosphonull S309A mutants and then were subjected to 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h. F Phase-contrast imaging assay of OVCAR8 cells. The red arrowheads indicate the large bubbles emerging from the plasma membrane. Scale bar = 100 μm. Representative images ( G ) and quantification ( H ) of the PI+ cells (red) and YP1+ cells (green). Scale bar = 100 μm. I Comparison of LDH release-based cell death. J The validation of ZBP1-S309 antibody using dot-blot assay. The vertical axis represents the concentration of the antibody. K In vitro phosphorylation assay of ZBP1 by purified protein AURKB or CDK1. L Immunoblot analysis in OVCAR8 cells after treated by 250 nM Talazoparib and 2.5 μM Ceralasertib and/or 1 μM Barasertib for 24 h. M After treating with 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h, OVCAR8 cells were shaken off to enrich mitotic cells and then treated with 1 μM Barasertib for 6 h. Immunoblot analysis of pAURKB, AURKB, pZBP1, and ZBP1 in OVCAR8 cells. GAPDH was used as the internal control. Representative images ( N ) and quantification ( O ) of the PLA to detect the physical association between AURKB and pZBP1-S309. Scale bar = 20 μm. P CO-IP assay to assess the interactions among ZBP1, RIPK1, CASP8, and CASP6 after transfected with Myc-tagged ZBP1 or its phosphonull S309A mutants and treated with 250 nM Talazoparib and 2.5 μM Ceralasertib in 293T cells. CASP8: caspase 8, CASP6: caspase 6. Q Schematic overview of the mechanism of DDR inhibitors-induced PANoptosis during aberrant mitotic progression. Created in BioRender. Liao, Z. (2025) https://BioRender.com/bstbek5 . The data in ( H , I , O ) are representative of three independent experiments and presented as the mean ± SEM. Data were repeated thrice independently in ( A , C , D , F , K – M , P ) with similar results. Statistical significance was determined using two-tailed Student’s t test in ( O ) and one-way ANOVA with Tukey’s multiple comparisons test in ( H , I ). Source data are provided as a file.

    Journal: Nature Communications

    Article Title: Aurora kinase B phosphorylates ZBP1 to drive PANoptosis following treatment with PARP and ATR inhibitors combination

    doi: 10.1038/s41467-025-66591-1

    Figure Lengend Snippet: A Immunoprecipitation assay indicates ZBP1 phosphorylation levels in 293T cells transfected with Myc-tagged ZBP1 and HA-tagged AURKB or its phosphonull TA mutants. Immunoprecipitated ZBP1 was probed with anti-phosphor-ser/thr antibody. B A schematic of the human ZBP1 sequence highlighting the phosphorylation sites observed by MS is shown. Fold changes in the abundance of phosphorylated peptides of ZBP1 in 293T cells transfected with AURKB-WT relative to 293T cells transfected with vectors are shown. Dots indicate data from three independent experiments. Additionally, fold changes in the abundance of phosphorylated peptides of ZBP1 in 293T cells transfected with AURKB-TA relative to 293T cells transfected with AURKB-WT are shown. C , D After the KD of ZBP1, OVCAR8 cells were transfected with plasmids expressing Myc-tagged ZBP1 or its phosphonull mutants and then were subjected to 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h. Immunoblot analysis of ZBP1, GSDME, PARP1, pMLKL, and tMLKL. GAPDH was used as the internal control. E The S309 phosphorylation site of ZBP1 in 293T cells after treated with 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h was analyzed by LC-MS/MS. F – I After the KD of ZBP1, OVCAR8 cells were transfected with plasmids expressing Myc-tagged ZBP1 or its phosphonull S309A mutants and then were subjected to 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h. F Phase-contrast imaging assay of OVCAR8 cells. The red arrowheads indicate the large bubbles emerging from the plasma membrane. Scale bar = 100 μm. Representative images ( G ) and quantification ( H ) of the PI+ cells (red) and YP1+ cells (green). Scale bar = 100 μm. I Comparison of LDH release-based cell death. J The validation of ZBP1-S309 antibody using dot-blot assay. The vertical axis represents the concentration of the antibody. K In vitro phosphorylation assay of ZBP1 by purified protein AURKB or CDK1. L Immunoblot analysis in OVCAR8 cells after treated by 250 nM Talazoparib and 2.5 μM Ceralasertib and/or 1 μM Barasertib for 24 h. M After treating with 250 nM Talazoparib and 2.5 μM Ceralasertib for 24 h, OVCAR8 cells were shaken off to enrich mitotic cells and then treated with 1 μM Barasertib for 6 h. Immunoblot analysis of pAURKB, AURKB, pZBP1, and ZBP1 in OVCAR8 cells. GAPDH was used as the internal control. Representative images ( N ) and quantification ( O ) of the PLA to detect the physical association between AURKB and pZBP1-S309. Scale bar = 20 μm. P CO-IP assay to assess the interactions among ZBP1, RIPK1, CASP8, and CASP6 after transfected with Myc-tagged ZBP1 or its phosphonull S309A mutants and treated with 250 nM Talazoparib and 2.5 μM Ceralasertib in 293T cells. CASP8: caspase 8, CASP6: caspase 6. Q Schematic overview of the mechanism of DDR inhibitors-induced PANoptosis during aberrant mitotic progression. Created in BioRender. Liao, Z. (2025) https://BioRender.com/bstbek5 . The data in ( H , I , O ) are representative of three independent experiments and presented as the mean ± SEM. Data were repeated thrice independently in ( A , C , D , F , K – M , P ) with similar results. Statistical significance was determined using two-tailed Student’s t test in ( O ) and one-way ANOVA with Tukey’s multiple comparisons test in ( H , I ). Source data are provided as a file.

    Article Snippet: Flag-tagged recombinant human AURKB protein was purchased from Proteintech (Cat: 81352), GST-tagged recombinant human CDK1 & Cyclin B1 protein was obtained from SinoBiological (Cat: C22B-10G), and GST-tagged recombinant human ZBP1 protein was obtained from CUSABI (Cat: CSB- EP861990 ).

    Techniques: Immunoprecipitation, Phospho-proteomics, Transfection, Sequencing, Expressing, Western Blot, Control, Liquid Chromatography with Mass Spectroscopy, Imaging, Clinical Proteomics, Membrane, Comparison, Biomarker Discovery, Dot Blot, Concentration Assay, In Vitro, Purification, Co-Immunoprecipitation Assay, Two Tailed Test